
Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The anxiety and depression treatment market was valued at USD 12.18 Billion in 2024, driven by the rising prevalence of mental health disorders across the 8 major markets. The market is anticipated to grow at a CAGR of 3.10% during the forecast period of 2025-2034 to achieve a value of USD 16.53 Billion by 2034. The growing awareness and acceptance of mental health conditions are driving increased demand for innovative treatments for anxiety and depression.
Base Year
Historical Period
Forecast Period
The rising awareness and acceptance of mental health issues are increasing demand for innovative anxiety and depression treatments.
Technological advancements like brain stimulation devices are expected to revolutionize non-pharmacological treatment approaches for mental health.
Pharmaceutical innovations and FDA approvals for novel antidepressants are accelerating market growth and expanding therapeutic options for patients.
Compound Annual Growth Rate
3.1%
Value in USD Billion
2025-2034
Anxiety and Depression Treatment Market Outlook
*this image is indicative*
Anxiety and depression are common mental health disorders characterized by persistent worry, fear, sadness, and loss of interest. These conditions can affect mood, behavior, and daily functioning. According to the World Health Organization (WHO), an estimated 3.8% of the global population experiences depression, including 5% of adults—4% of men and 6% of women—and 5.7% of individuals over the age of 60. Treatment typically includes a combination of antidepressant medications such as SSRIs or SNRIs, therapy like Cognitive Behavioral Therapy (CBT), and emerging technologies like brain stimulation devices. The market is anticipated to grow at a CAGR of 3.10% during the forecast period of 2025-2034. Early diagnosis and personalized treatment plans are essential for effective symptom management and improved quality of life.
Innovative Therapies and Rising Mental Health Awareness Driving Market Growth
The growing prevalence of treatment-resistant depression and the urgent need for effective therapies are key drivers of the anxiety and depression treatment market. For instance, in January 2025, Johnson & Johnson secured FDA approval for SPRAVATO® (esketamine) nasal spray as the first monotherapy for adults with major depressive disorder who do not respond to at least two oral antidepressants. This approval addresses a significant unmet need, enhancing treatment options and is expected to accelerate market expansion during the forecast period.
Rise in Clinical Trial Initiatives to Meet Rising Anxiety and Depression Treatment Market Demand
Increasing focus on novel drug delivery methods and better understanding of social anxiety disorder (SAD) epidemiology are important market drivers. For instance, in April 2025, Vistagen presented new data on SAD and age of onset from its Phase 3 program at the Anxiety and Depression Association of America Conference. This research strengthens knowledge of SAD prevalence in young adults, supporting the development of innovative intranasal treatments that could expand therapeutic options and stimulate growth in the anxiety and depression treatment market over the forecast period.
Some of the notable trends include growing initiatives to make the masses aware of mental health conditions like depression and anxiety, adoption of digital tools for easy management and diagnosis, along with
Anxiety and Depression Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Breakup by Indication
Market Breakup by Age Group
Market Breakup by Distribution Channel
Market Breakup by Region
Selective Serotonin Reuptake Inhibitors (SSRIs) to Lead the Segmentation by Treatment Type
Selective serotonin reuptake inhibitors (SSRIs) are expected to hold the largest share in the market due to their proven efficacy, minimal side effects, and first-line use in clinical guidelines. As more individuals are diagnosed early and seek medical help, SSRIs remain the preferred initial pharmacological intervention. Their availability in generics, growing awareness, and rising healthcare access make SSRIs the most prescribed and widely accepted treatment option, thus driving long-term market expansion during the forecast period.
Major Depressive Disorder (MDD) to Hold a Substantial Anxiety and Depression Treatment Market Value by Indication
Major depressive disorder (MDD) is anticipated to dominate the indication segment due to its high global prevalence and increasing diagnosis rates. The World Health Organization reports that globally, around 280 million people are affected by depression. The condition is approximately 50% more prevalent in women than in men. Additionally, over 10% of pregnant women and new mothers suffer from depression. Each year, more than 700,000 people die by suicide, making it the fourth leading cause of death among individuals aged 15 to 29. Innovations in treatment-resistant depression therapies and growing public awareness have fueled demand. As clinical focus sharpens on personalized and early interventions, MDD remains a central area for treatment development, positioning it to lead the market throughout the forecast period.
The United States is expected to dominate the market due to its leadership in neurotechnology innovation and early regulatory approvals. For instance, in March 2025, the FDA granted breakthrough device designation to a novel non-invasive brain stimulation system developed by Pulvinar Neuro for treating psychiatric disorders. With strong R&D backing and rapid clinical adoption, the United States continues to outpace Europe and Asia in translating neuroscience breakthroughs into commercial treatments, solidifying its market leadership.
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in New York City and founded in 1849, Pfizer Inc. is a global pharmaceutical giant known for developing innovative therapies across various therapeutic areas. In the mental health segment, Pfizer’s portfolio includes antidepressants and anti-anxiety medications, notably Zoloft and Effexor XR. The company continues to invest in neuroscience research to expand its footprint in psychiatric treatment.
GlaxoSmithKline plc (GSK), based in Brentford, United Kingdom, was established in 2000 following the merger of Glaxo Wellcome and SmithKline Beecham. GSK’s neuroscience portfolio includes medications for depression and anxiety such as Paxil and Lamictal. The company also supports mental health treatment access initiatives in low-income countries, furthering its role in the global psychiatric drug market.
Founded in 1999 and headquartered in Cambridge, United Kingdom, AstraZeneca plc is a multinational pharmaceutical company with a presence in mental health through products like Seroquel, used for mood disorders. While it has shifted focus to oncology and cardiovascular areas, AstraZeneca’s historical role in psychiatric treatment continues to influence market trends and generic development.
Established in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Co. is a prominent player in mental health pharmaceuticals. Its widely used antidepressants and antipsychotic drugs, including Prozac, Cymbalta, and Zyprexa, have set benchmarks in depression and anxiety treatment. The company remains committed to neuroscience innovation through ongoing research and clinical development.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Sanofi SA, Johnson & Johnson Innovative Medicine, AbbVie Inc., Viatris Inc., Abbott Laboratories, Teva Pharmaceutical Industries Ltd., and Apotex Corporation.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
REPORT FEATURES | DETAILS |
Base Year | 2024 |
Historical Period | 2018-2024 |
Forecast Period | 2025-2034 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Drug Class |
|
Breakup by Indication |
|
Breakup by Age Group |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.